Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: A critical review

被引：34

作者：

Abbott J. ^{[1
]}

Hart A. ^{[1
]}

机构：

[1] Faculty of Health, University of Central Lancashire

来源：

Health and Quality of Life Outcomes | / 3卷 / 1期

关键词：

Cystic Fibrosis; Hypertonic Saline; Minimal Clinically Important Difference; Dornase Alfa; Chronic Respiratory Disease Questionnaire;

D O I：

10.1186/1477-7525-3-19

中图分类号：

学科分类号：

摘要：

Good quality clinical trials are essential to inform the best cystic fibrosis (CF) management and care, by determining and comparing the effectiveness of new and existing therapies and drug delivery systems. The formal inclusion of quality of life (QoL) as an outcome measure in CF clinical trials is becoming more common. Both an appropriate QoL measure and sound methodology are required in order to draw valid inferences about treatments and QoL. A review was undertaken of randomised controlled trials in cystic fibrosis where QoL was measured. EMBASE, MEDLINE and ISI Web of Science were searched to locate all full papers in the English language reporting randomised controlled trials in cystic fibrosis, published between January 1991 and December 2004. All Cochrane reviews published before December 2004 were hand searched. Papers were included if the authors had reported that they had measured QoL or well being in the trial. 16 trials were identified. The interventions investigated were: antibiotics (4); home versus hospital administration of antibiotics (1); steroids (1); mucolytic therapies (6); exercise (3) and pancreatic enzymes (1). Not one trial evaluated in this review provided conclusive results concerning QoL. This review highlights many of the pitfalls of QoL measurement in CF clinical trials and provides constructive information concerning the design and reporting of trials measuring QoL. © 2005 Abbott and Hart, licensee BioMed Central Ltd.

引用

页数：12

共 46 条

[1]

Kerem B.S., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., Buchwald M., Tsui L.C., Identification of the cystic fibrosis gene: Genetic analysis, Science, 245, pp. 1073-1080, (1989)

[2]

Welsh M.J., Electrolyte transport by airway epithelia, Physiol. Rev., 67, pp. 1143-1164, (1990)

[3]

Dodge J.A., Morison S., Lewis P.A., Coles E.C., Geddes D., Russell G., Littlewood J.M., Scott M.T., Incidence, population and survival of cystic fibrosis in the UK (1968-95), Arch. Dis. Child, 77, pp. 493-496, (1997)

[4]

1995 Annual Data Report, (1996)

[5]

Elborn J.S., Britton J.R., Shale D.J., Cystic fibrosis: Current survival and population predictions until the year 2000, Thorax, 46, pp. 881-885, (1991)

[6]

Kerem E., Corey M., Gold R., Levinson H., Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa, J. Pediatr., 116, pp. 714-719, (1990)

[7]

Pamukcu A., Bush A., Buchdahl R., Effects of Pseudomonas aeruginosa colonisation on lung function and anthropomorphic variables in children with cystic fibrosis, Pediatr. Pulmonol., 19, pp. 10-15, (1995)

[8]

Moher D., Schulz K.F., Altman D., The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials, JAMA, 285, pp. 1987-1991, (2001)

[9]

Doring G., Conway S.P., Heijerman H.G.M., Hodson M., Hoiby N., Smyth A., Touw D.J., Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European Consensus, Eur. Respir. J., 16, pp. 749-767, (2000)

[10]

Patient Registry 1996 Annual Data Report, (1997)

← 1 2 3 4 5 →